RT Journal Article
SR Electronic
T1 Gastrointestinal involvement attenuates COVID-19 severity and mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.07.20187666
DO 10.1101/2020.09.07.20187666
A1 Livanos, Alexandra E.
A1 Jha, Divya
A1 Cossarini, Francesca
A1 Gonzalez-Reiche, Ana S.
A1 Tokuyama, Minami
A1 Aydillo, Teresa
A1 Parigi, Tommaso L.
A1 Ramos, Irene
A1 Dunleavy, Katie
A1 Lee, Brian
A1 Dixon, Rebekah
A1 Chen, Steven T.
A1 Martinez-Delgado, Gustavo
A1 Nagula, Satish
A1 Ko, Huaibin M.
A1 Reidy, Jason
A1 Naymagon, Steven
A1 Grinspan, Ari
A1 Ahmad, Jawad
A1 Tankelevich, Michael
A1 Gordon, Ronald
A1 Sharma, Keshav
A1 Britton, Graham J.
A1 Chen-Liaw, Alice
A1 Spindler, Matthew P.
A1 Plitt, Tamar
A1 Wang, Pei
A1 Cerutti, Andrea
A1 Faith, Jeremiah J.
A1 Colombel, Jean-Frederic
A1 Kenigsberg, Ephraim
A1 Argmann, Carmen
A1 Merad, Miriam
A1 Gnjatic, Sacha
A1 Harpaz, Noam
A1 Danese, Silvio
A1 Rahman, Adeeb
A1 Kumta, Nikhil A.
A1 Aghemo, Alessio
A1 Petralia, Francesca
A1 Bakel, Harm van
A1 Garcia-Sastre, Adolfo
A1 Mehandru, Saurabh
YR 2020
UL http://medrxiv.org/content/early/2020/09/09/2020.09.07.20187666.abstract
AB Given that gastrointestinal (GI) symptoms are a prominent extrapulmonary manifestation of coronavirus disease 2019 (COVID-19), we investigated the impact of GI infection on disease pathogenesis in three large cohorts of patients in the United States and Europe. Unexpectedly, we observed that GI involvement was associated with a significant reduction in disease severity and mortality, with an accompanying reduction in key inflammatory proteins including IL-6, CXCL8, IL-17A and CCL28 in circulation. In a fourth cohort of COVID-19 patients in which GI biopsies were obtained, we identified severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) within small intestinal enterocytes for the first time in vivo but failed to obtain culturable virus. High dimensional analyses of GI tissues confirmed low levels of cellular inflammation in the GI lamina propria and an active downregulation of key inflammatory genes including IFNG, CXCL8, CXCL2 and IL1B among others. These data draw attention to organ-level heterogeneity in disease pathogenesis and highlight the role of the GI tract in attenuating SARS-CoV-2-associated inflammation with related mortality benefit.Competing Interest StatementA.E.L.: none, D.J.: none, F.C.: none, A.S.G-R.: none, M.T.: none, T.A.: none, T.L.P.: none, I.R.: none, K.D.: none, B.L.: none, R.D.: none, S.T.C.: none, G.M.D.: none, S.N.: none, H.M.K.: none, J.R.: none, S.N.: none, A.G.: none, J.A.: none, M.T.: none, R.G.: none, K.S.: none, G.J.B.: none, A.C.L.: none, M.P.S.: none, T.P.: none, P.W.: none, A.C.: none J.J.F.: Serves on the scientific advisor board of Vedanta Biosciences and has received grants from Janssen (unrelated to this work), J.F.C.: Serves as a consultant for the following companies (all unrelated to this work): Abbvie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporations, Celltrion, Eli Lilly, Enterome. E.K.: none, C.A.: none, M.M.: Discloses the following (unrelated to this work): Takeda, Genentech, Regeneron, Compugen, Myeloid Therapeutics, S.G.: Discloses receiving research grants from the following: Bristol Myers Squibb, Genentech, Immune Design, Agenus, Janssen. Also discloses serving as consultant for Merck, OncoMed and Neon Therapeutics. N.H.: Discloses serving as consultant for Lilly USA and pathology service contract with Abbvie and Celgene. S.D.: Discloses serving as a consultant for Ely Lilly, Enthera, Ferring Pharmaceuticals, Gilead, Hospira, Inotrem, Janssen, Johnson&Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB, Vifor. A.R.: none, N.A.K.: Discloses serving as a consultant for Apollo Endosurgery, Boston Scientific, Gyrus AMCI, Olympus. A.A.: none, F.P.: none, H.V.B.: none, A.G.S.: S.M.: none.Funding StatementThis research was partly funded by NIH/NIDDK123749 (SM). Additional support was provided by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), and NIAID R01AI113186 (to H.B). Additionally, the work was supported by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)), Defense Advanced Research Projects Agency and anonymous donors to AG-S. MT was funded by the Digestive Disease Research Foundation (DDRF). A.S.G-R. is supported in part by a Robin Chemers Neustein Postdoctoral Fellowship Award. S.T.C. is supported by grant F30CA243210. G.J.B. is supported by a Research Fellowship Award from the Crohns and Colitis Foundation of America. M.P.S. is supported by NIH T32 5T32AI007605. S.G. is supported by grants U24 CA224319, U01 DK124165, and P01 CA190174. We also thank Randy Albrecht for support with the BSL3 facility and procedures at the Icahn School of Medicine at Mount Sinai (ISMMS). The research carried out by H.V.B and A.S.G-R was supported by the Office of Research Infrastructure of the National Institutes of Health (NIH) under awards S10OD018522 and S10OD026880. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were approved by the institutional review board (IRB) of the Icahn School of Medicine at Mount Sinai under the following protocols: IRB-20-03297A North American registry of the digestive manifestations of COVID-19 IRB 16-0583, The impact of viral infections and their treatment on gastrointestinal immune cellsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMass cytometry and RNA sequencing data are provided in the supplementary information.